Category: IRDiRC

Happy Holidays from IRDiRC

IRDiRC in 2023 – Four new Task Forces, numerous publications, RE(ACT) Congress, World Orphan Drug Congress participation and the list goes on! We couldn’t have had such a successful year without you! We are sending our sincere gratitude to the Rare Disease community for the fantastic work and involvement towards the common mission of improving […]

Read More

Just two months until application submission – FDA Office of Orphan Products Development Natural History Studies grant funding opportunity

The grant application submission deadline is coming up in just 2 months! The application submission deadline for this grant funding opportunity is February 13, 2024.  Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) The purpose of this grant is to support efficient and innovative natural history studies that advance medical product development in rare […]

Read More

CDER: Patient Community Engagement Public Meeting

On December 14, CDER and Duke-Margolis will host a jointly sponsored virtual public meeting on advancing the development of therapeutics through rare disease patient community engagement. The purpose of this public meeting is to highlight and build upon existing actionable approaches for engaging patients, patient groups, and related experts when developing necessary evidence to support […]

Read More

The Chan Zuckerberg Initiative (CZI) is expanding the Rare As One Network and a new cycle will be open next year (including for organisations outside the USA). A call for applications is now in effect. CZI has funded 2 Cycles so far, and learned how successfully patient organisations are engaging in research collaborations, generating significant […]

Read More

Scientific Call for Proposals AFM-TÉLÉTHON 2024

AFM-Téléthon opens the call for proposals for 2024, open to both French and foreign teams, that aims to support research along the following thematics: A. Fundamental research and physiopathology of diseases of the neuromuscular system B. Development of innovative therapeutic approaches for rare genetic diseases The selected projects will be subject to an agreement with […]

Read More

FDA Office of Orphan Products Development: Natural History Studies grant funding opportunity

The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) announces the availability of funds for fiscal year (FY) 2024 to support natural history studies for rare diseases and conditions. This funding opportunity is intended to support prospective or retrospective, efficient, and innovative natural history studies with a focus on collaborative and standardized approaches to […]

Read More

The 2024 edition of the International Myotonic Dystrophy Consortium Meeting (IDMC-14) will be held in Nijmegen from 9-13 April 2024

Nijmegen is the oldest city in the Netherlands and one of the places where the disease-causing repeat expansion was identified in the nineties. OPTIMISTIC, the largest myotonic dystrophy trial, was initiated and coordinated in Nijmegen.   The meeting will offer an excellent opportunity to learn, share, and network with all those currently active in the field of myotonic dystrophy: […]

Read More

European Conference on Rare Diseases and Orphan Products (ECRD) – 15-16 May 2024 (Brussels and online)

The 12th European Conference on Rare Diseases and Orphan Products (ECRD) will take place on 15-16 May 2024, both online and in Brussels! It will be held as an official event under the auspices of the Belgian EU Council Presidency. ECRD is the largest, patient-led, rare disease policy-shaping event held in Europe, aimed at identifying key priorities to forge a unified approach for the […]

Read More